NewsBenzingaCanaccord Genuityがバイオジェンの「買い」を継続、目標株価を272ドルに引き上げ Canaccord Genuityがバイオジェンの「買い」を継続、目標株価を272ドルに引き上げ Benzinga 2026.10.29 21:56 (GMT+0) Open on Benzinga Other news Alphabet Suffers Record Drop, Pulls Other Tech Stocks Lower Alphabet: Rocked By Cash Flows, But Don't Fret (NASDAQ:GOOG) Amazon.com, Inc. (AMZN) Q3 2026 Earnings Call Transcript Sterling Infrastructure, Inc. (STRL) Q3 2026 Earnings Call Transcript Credit Acceptance Corporation (CACC) Q3 2026 Earnings Call Transcript NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
